Information Provided By:
Fly News Breaks for May 23, 2018
CARA
May 23, 2018 | 12:42 EDT
H.C. Wainwright analyst Oren Livnat said Cara Therapeutics selected the "best possible partner to maximize IV Korsuva" in signing an agreement with the Vifor/Fresenius joint venture. He views the deal as a "clear positive," stating that it brings in minimally dilutive financing, validates Korsuva, and de-risks the U.S. commercial launch. Livnat increased his price target on Cara shares to $24 from $22 and keeps a Buy rating on the stock.
News For CARA From the Last 2 Days
There are no results for your query CARA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.